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Purpose: To report a case of refractory ocular hypotony due to chronic Behcet’s disease
with good response to high-dose topical latanoprost.
Case Report: We present a 26-year-old man with a known history of Behcet’s disease
who developed decreasing vision and severe ocular hypotony that was refractory to
multiple treatment modalities including subtenon triamcinolone acetonide, ibopamine,
pars plana vitrectomy, and silicone oil injection. We decided to try high-dose topical
latanoprost for the management of ocular hypotony based on recent reports. After six
months, intraocular pressure (IOP) increased by 5 mm Hg, became stable at 7 mm Hg,
and remained unchanged at month 24.
Conclusion: High-dose topical latanoprost could lead to significant increase in IOP in
uveitis-induced refractory ocular hypotony.
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INTRODUCTION
Ocular hypotony is one of the complications of
uveitis and causes substantial visual loss. It occurs
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because of hyposecretion of the ciliary body owing
to inflammation and increased uveoscleral outflow.
In the acute phase of the disease, it is usually
reversible; and suppressing the inflammation
by corticosteroids or other anti-inflammatory
medications may restore the intraocular pressure
(IOP). However, in chronic uveitis, long-term
inflammation can lead to structural changes such
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as growth of tractional membranes on the ciliary
body and atrophic changes resulting in long-lasting
or irreversible hypotony. Chronic ocular hypotony
is associated with sight-threatening complications
including hypotony maculopathy, choroidal folds,
and optic nerve edema.[1–3] Ocular hypotony is
defined as IOP< 8mmHg, andmost complications
arise when IOP is < 4 mm Hg.[4]
CASE REPORT
In this report, we present a 26-year-old male
with a past medical history of Behcet’s disease
who developed progressive vision loss and
severe hypotonia. He had received 15 mg of
methotrexate weekly and 7.5 mg of prednisolone
daily as well as multiple injections of subtenon
triamcinolone acetonide (TA; 40 mg). He had also
undergone phacoemulsification and posterior
chamber intraocular lens placement for cataract in
his both eyes. Pars plana vitrectomy with silicone
oil injection was performed in his right eye for
hypotony. Visual acuity was 20/400 in his right
eye and “hand motion” in his left eye. Ocular
hypotony persisted despite all these treatments in
the absence of active inflammation. Corneal folds
and band keratopathy were noted after few weeks.
Fundus was poorly visible but it was remarkable
for cystic changes in the macular region. B-scan
showed a significant serous choroidal detachment
due to severe hypotony in both eyes. To increase
the IOP, multiple injections of 40 mg of subtenon
and 4 mg of intravitreal TA were administered;
however, no improvement was observed in vision,
IOP status, and serous choroidal detachment.
Visual acuity deteriorated because of persistent
hypotony maculopathy. Ibopamine (a dopamine
agonist) eye drops were used for three months
with an increase in IOP of 2 mm Hg in both the
eyes, but no change in vision was detected.
We discussed the details of our experimental
treatment based on published studies with the
patient and proceeded with the treatment after
obtaining a written consent. Subsequently, high-
dose latanoprost eye drops (XALATAN, 0.005%,
Pfizer) were administered every 6 hours in both
eyes.
One month later, IOP increased to 4 mm Hg,
and at two months, to 7 mm Hg. After two
months of latanoprost treatment, we performed a
drug rechallenge test by discontinuing latanoprost
for four weeks and then resuming the drug to
prove its effect on IOP. After 6 months, IOP was
stable at 7 mm Hg and remained unchanged
even after 24 months. B-scan showed significant
improvement in hypotony maculopathy and fluid
resolved subretinally (Figures 1B and D). The
patient’s vision improved to 20/200 in his right eye
and “finger counting” at 1.5 m in his left eye.
DISCUSSION
Chronic ciliary body inflammation leads to traction
on the ciliary body, atrophic changes of this
tissue, and subsequent ocular hypotony. Serous
choroidal detachment can occur because of
chronic hypotony. If ciliary body traction or
detachment is visible on ultrasound biomicroscopy,
vitrectomy and membranectomy with or without
silicone oil injection may be used to improve the
IOP. For our patient, although we performed a
vitrectomy with silicone oil injection in the right
eye, IOP did not change. In such cases, the rise in
IOP may be temporary and mandate reinjection of
silicone oil in approximately 50% of patients.[1–3]
Ibopamine is a dopamine agonist that can increase
aqueous humor secretion and IOP. Administration
of ibopamine eye drops increases the IOP by
approximately 2 mm Hg.[5] In our case, ibopamine
improved IOP to a barely measurable 2 mm
Hg. Subtenon and intravitreal injections of TA
or systemic corticosteroids may increase IOP in
chronic hypotony.[6, 7] However, these treatments
did not improve results in our patient.
Prostaglandins (PGs) play an important role
in aqueous humor dynamics. Latanoprost is a
selective PGF2 receptor agonist that can reduce
IOP by increasing aqueous outflow mostly by
increasing the uveoscleral outflow. It is a potent
antiglaucoma treatment when applied once
daily.[8] However, when administered topically
at high concentrations or intracamerally, PGs
E and F can cause miosis and raise the IOP.
At the same time, they increase the protein
content and white blood cells in the aqueous
humor.[9]
In chronic uveitis, ciliary body atrophy and
consequent aqueous hyposecretion may be
difficult to overcome; and decreasing aqueous
outflow may be a better way to restore the
IOP. High-dose latanoprost may cause some
grades of inflammation in trabecular meshwork
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Figure 1. (A) Right eye B-scan before latanoprost treatment. (B) Serous choroidal detachment resolution after treatment with high-
dose latanoprost in the right eye. (C) Left eye B-scan before latanoprost treatment. (D) Serous choroidal detachment improvement
after treatment in the left eye.
and reduce the aqueous outflow. In cases
with no tractional membranes on the ciliary
body, it may be more practical to increase
the uveoscleral outflow. This could be a
mechanism by which high-dose latanoprost
can raise the IOP in similar cases as our
patient. Another less possible mechanism
could be improvement of the serous choroidal
detachment due to an increase in uveoscleral
outflow.
In a report of three cases with uveitic glaucoma,
latanoprost had a paradoxical impact on IOP.[10]
Latanoprost significantly increased IOP, and
a latanoprost rechallenge test—performed by
discontinuing and then continuing the drug—
proved that latanoprost could increase the
IOP. All patients had uveitis; thus, it can be
postulated that in the presence of a severely
damaged blood-ocular barrier, latanoprost can
have a paradoxical impact on IOP. In that report,
latanoprost was administered at a therapeutic
once daily dose, and it may be assumed that
higher doses, as in our case, may have a
more prominent impact on IOP. Higher doses
of latanoprost may result in more PG release from
the impaired blood-ocular barrier and trabecular
inflammation, which can overcome the increase in
uveoscleral aqueous outflow and result in raised
IOP.[10]
Latanoprost has reportedly been used in
uveitic patients without the risk of central macular
edema or recurrence of anterior uveitis.[11] In
patients with anterior and intermediate uveitis,
low-dose (once daily) latanoprost did not
show higher rates of inflammation recurrence
when compared to a fixed combination of
dorzolamide and timolol.[12] However, similar
findings have not been seen in patients with
severe posterior uveitis due to Behcet’s disease.
Therefore, despite it appearing paradoxical
to use latanoprost as an IOP-recovering
agent in a uveitic patient, its effect might be
dependent on the type, severity, and chronicity of
uveitis.
It can be concluded that, in some cases,
high-dose latanoprost can be administered as
an adjuvant treatment for refractory hypotony
due to chronic inflammation. Prospective
clinical trials to further investigate this can be
beneficial.
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